Literature DB >> 24045448

Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.

Luca Viganò1, Lorenzo Capussotti, Giovanni De Rosa, Wassila Oulhaci De Saussure, Gilles Mentha, Laura Rubbia-Brandt.   

Abstract

OBJECTIVES: We analyzed the impact of chemotherapy-related liver injuries (CALI), pathological tumor regression grade (TRG), and micrometastases on long-term prognosis in patients undergoing liver resection for colorectal metastases after preoperative chemotherapy.
BACKGROUND: CALI worsen the short-term outcomes of liver resection, but their impact on long-term prognosis is unknown. Recently, a prognostic role of TRG has been suggested. Micrometastases (microscopic vascular or biliary invasion) are reduced by preoperative chemotherapy, but their impact on survival is unclear.
METHODS: Patients undergoing liver resection for colorectal metastases between 1998 and 2011 and treated with oxaliplatin and/or irinotecan-based preoperative chemotherapy were eligible for the study. Patients with operative mortality or incomplete resection (R2) were excluded. All specimens were reviewed to assess CALI, TRG, and micrometastases.
RESULTS: A total of 323 patients were included. Grade 2-3 sinusoidal obstruction syndrome (SOS) was present in 124 patients (38.4%), grade 2-3 steatosis in 73 (22.6%), and steatohepatitis in 30 (9.3%). Among all patients, 22.9% had TRG 1-2 (major response), whereas 55.7% had TRG 4-5 (no response). Microvascular invasion was detected in 37.8% of patients and microscopic biliary infiltration in 5.6%.The higher the SOS grade the lower the pathological response: TRG 1-2 occurred in 16.9% of patients with grade 2-3 SOS versus 26.6% of patients with grade 0-1 SOS (P = 0.032).After a median follow-up of 36.9 months, 5-year survival was 38.6%. CALI did not negatively impact survival. Multivariate analysis showed that grade 2-3 steatosis was associated with better survival than grade 0-1 steatosis (5-year survival rate of 52.5% vs 35.2%, P = 0.002). TRG better than the percentage of viable cells stratified patient prognosis: 5-year survival rate of 60.4% in TRG 1-2, 40.2% in TRG 3, and 29.8% in TRG 4-5 (P = 0.0001). Microscopic vascular and biliary invasion negatively impacted outcome (5-year survival rate of 23.3% vs 45.7% if absent, P = 0.017; 0% vs 42.3%, P = 0.032, respectively).
CONCLUSIONS: TRG was confirmed to be a crucial prognostic determinant. CALI do not negatively impact long-term prognosis, but the tumor response is reduced in patients with grade 2-3 SOS. Steatosis was found to have a protective effect on survival. Micrometastases significantly impacted prognosis assessment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24045448     DOI: 10.1097/SLA.0b013e3182a6183e

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  49 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis.

Authors:  Damien Bergeat; Michel Rayar; Yann Mouchel; Aude Merdrignac; Bernard Meunier; Astrid Lièvre; Karim Boudjema; Laurent Sulpice
Journal:  Langenbecks Arch Surg       Date:  2017-01-13       Impact factor: 3.445

Review 3.  [Assessment of resectability of colorectal liver metastases and extended resection].

Authors:  U Settmacher; H Scheuerlein; F Rauchfuss
Journal:  Chirurg       Date:  2014-01       Impact factor: 0.955

4.  Response to: "Liver Resection and Role of Extended Cytology and Histology".

Authors:  Luca Vigano; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

5.  Chemotherapy-Associated Liver Injuries: Unmet Needs and New Insights for Surgical Oncologists.

Authors:  Luca Vigano; Martina Sollini; Francesca Ieva; Francesco Fiz; Guido Torzilli
Journal:  Ann Surg Oncol       Date:  2021-04-30       Impact factor: 5.344

Review 6.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

7.  A Low Neutrophil to Lymphocyte Ratio Before Preoperative Chemotherapy Predicts Good Outcomes After the Resection of Colorectal Liver Metastases.

Authors:  Rui Mao; Jian-Jun Zhao; Xin-Yu Bi; Ye-Fan Zhang; Zhi-Yu Li; Zhen Huang; Jian-Guo Zhou; Hong Zhao; Jian-Qiang Cai
Journal:  J Gastrointest Surg       Date:  2018-07-31       Impact factor: 3.452

8.  Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.

Authors:  Luca Viganò; Vittorio Pedicini; Tiziana Comito; Carlo Carnaghi; Guido Costa; Dario Poretti; Ciro Franzese; Nicola Personeni; Daniele Del Fabbro; Lorenza Rimassa; Marta Scorsetti; Armando Santoro; Luigi Solbiati; Guido Torzilli
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

9.  R1 Resection for Colorectal Liver Metastases: a Survey Questioning Surgeons about Its Incidence, Clinical Impact, and Management.

Authors:  Luca Viganò; Guido Costa; Matteo Maria Cimino; Fabio Procopio; Matteo Donadon; Daniele Del Fabbro; Jacques Belghiti; Norihiro Kokudo; Masatoshi Makuuchi; Jean-Nicolas Vauthey; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2018-06-08       Impact factor: 3.452

10.  [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro adjuvant chemotherapy].

Authors:  F Lordick; M Knödler; U Hacker; M Bartels
Journal:  Chirurg       Date:  2014-01       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.